Innate Pharma S.A.
IPHYF
$1.45
-$0.31-17.61%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.85% | -168.86% | 1.09% | -640.60% | 1.50% |
| Total Depreciation and Amortization | -0.85% | -20.36% | -1.08% | -60.33% | 1.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.91% | -80.17% | -1.07% | -81.79% | 1.50% |
| Change in Net Operating Assets | -0.85% | 297.77% | 1.09% | 26.82% | -1.50% |
| Cash from Operations | -0.85% | 114.51% | 1.09% | -83.96% | -1.50% |
| Capital Expenditure | 0.85% | -579.65% | 1.31% | 86.39% | -1.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -1.10% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.85% | -94.10% | -1.09% | 32,852.48% | 1.48% |
| Cash from Investing | -0.85% | -95.50% | -1.09% | 8,585.06% | -1.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -476.27% | 0.00% | 51.88% | 0.00% |
| Issuance of Common Stock | 0.00% | 97.87% | 0.00% | -86.49% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.85% | -505.96% | 1.07% | 42.22% | -1.50% |
| Foreign Exchange rate Adjustments | 0.86% | -301.01% | -1.14% | -11.03% | 1.41% |
| Miscellaneous Cash Flow Adjustments | 0.00% | 200.00% | 0.00% | -200.00% | 0.00% |
| Net Change in Cash | 0.84% | 23.25% | 1.09% | 93.69% | -1.50% |